Suppr超能文献

肝癌生物标志物的评估。

Assessment of liver cancer biomarkers.

作者信息

Mansouri Vahid, Razzaghi Mohhamadreza, Nikzamir Abdolrahim, Ahmadzadeh Alireza, Iranshahi Majid, Haghazali Mehrdad, Hamdieh Mostafa

机构信息

Proteomics Research Center, School of Rehabilitation, ShahidBeheshti University of Medical Sciences, Tehran, Iran.

Laser Application in Medical Sciences Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran.

出版信息

Gastroenterol Hepatol Bed Bench. 2020 Winter;13(Suppl1):S29-S39.

Abstract

Liver cancer is the third cause of cancer-related deaths in the world. It is primarily divides into two main types, namely hepatocellular carcinoma (HC) and cholangiocarcinoma (IC). Due to the increasing number of patients with liver cancer and the high mortality rate, early diagnosis of the disease can be helpful in treatment, but most patients are diagnosed atlate stages of HC. The aim of this study is to screen and provide an overview on candidate biomarkers related to primary liver cancer to introduce the critical ones. In this study, various biomarkers related to the diagnosis of primary liver cancer have been studied. Accordingly, biomarkers are divided into different groups as blood biomarkers classified as serum and plasma biomarkers, tissue biomarkers, microRNA biomarkers, proteomic biomarkers and altered genes. Previous researches have focused on liver cells and bile ducts, the surround cellular environment, how cells differentiate, and the types of genes expressed in liver cancer. Some even have focused on the origin of tumor cells and how they differentiate and develop. In all these studies, the expression of specific proteins and genes in liver cancer has been considered. Based on available sources, biomarkers can be considered as candidates to diagnose and prognosis of various types of primary liver cancer, from sources such as blood, tissue, mic-RNA, proteome and genes. However, more investigations are required to introduce a biomarker for precise detection of early liver cancer.

摘要

肝癌是全球癌症相关死亡的第三大原因。它主要分为两种主要类型,即肝细胞癌(HC)和胆管癌(IC)。由于肝癌患者数量不断增加且死亡率高,疾病的早期诊断有助于治疗,但大多数患者在肝细胞癌的晚期才被诊断出来。本研究的目的是筛选并概述与原发性肝癌相关的候选生物标志物,以介绍关键的生物标志物。在本研究中,对与原发性肝癌诊断相关的各种生物标志物进行了研究。因此,生物标志物被分为不同的组,如作为血清和血浆生物标志物分类的血液生物标志物、组织生物标志物、微小RNA生物标志物、蛋白质组学生物标志物和改变的基因。先前的研究集中在肝细胞和胆管、周围的细胞环境、细胞如何分化以及肝癌中表达的基因类型。有些甚至关注肿瘤细胞的起源以及它们如何分化和发展。在所有这些研究中,都考虑了肝癌中特定蛋白质和基因的表达。根据现有资料,生物标志物可被视为诊断和预测各种类型原发性肝癌的候选物,其来源包括血液、组织、微小RNA、蛋白质组和基因等。然而,需要更多的研究来引入一种用于精确检测早期肝癌的生物标志物。

相似文献

1
Assessment of liver cancer biomarkers.
Gastroenterol Hepatol Bed Bench. 2020 Winter;13(Suppl1):S29-S39.
2
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
World J Gastroenterol. 2020 Dec 28;26(48):7664-7678. doi: 10.3748/wjg.v26.i48.7664.
3
Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors.
J Cancer Res Clin Oncol. 2021 Jan;147(1):49-59. doi: 10.1007/s00432-020-03378-5. Epub 2020 Sep 12.
4
Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.
Biomark Cancer. 2016 Jul 4;8(Suppl 1):37-55. doi: 10.4137/BIC.S34413. eCollection 2016.
5
Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma.
PLoS One. 2020 Aug 26;15(8):e0238251. doi: 10.1371/journal.pone.0238251. eCollection 2020.
8
MicroRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.
Curr Drug Targets. 2019;20(11):1129-1140. doi: 10.2174/1389450120666190307095720.

引用本文的文献

2
Current status and new directions for hepatocellular carcinoma diagnosis.
Liver Res. 2024 Dec 5;8(4):218-236. doi: 10.1016/j.livres.2024.12.001. eCollection 2024 Dec.
3
Evaluation of glypican‑3 in patients with hepatocellular carcinoma.
Mol Clin Oncol. 2024 Oct 23;22(1):1. doi: 10.3892/mco.2024.2796. eCollection 2025 Jan.
6
Non-Coding RNA-Based Biosensors for Early Detection of Liver Cancer.
Biomedicines. 2021 Aug 5;9(8):964. doi: 10.3390/biomedicines9080964.

本文引用的文献

1
Biomarkers for hepatocellular cancer.
World J Hepatol. 2020 Sep 27;12(9):558-573. doi: 10.4254/wjh.v12.i9.558.
2
The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.
Cell Death Discov. 2020 Jun 19;6:53. doi: 10.1038/s41420-020-0287-y. eCollection 2020.
3
Progress and prospects of biomarkers in primary liver cancer (Review).
Int J Oncol. 2020 Jul;57(1):54-66. doi: 10.3892/ijo.2020.5035. Epub 2020 Apr 1.
4
How to improve HCC surveillance outcomes.
JHEP Rep. 2019 Nov 5;1(6):460-467. doi: 10.1016/j.jhepr.2019.10.007. eCollection 2019 Dec.
6
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.
Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052.
7
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.
Cancers (Basel). 2019 Sep 10;11(9):1339. doi: 10.3390/cancers11091339.
8
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer.
Front Oncol. 2019 Aug 2;9:708. doi: 10.3389/fonc.2019.00708. eCollection 2019.
9
Proteomic profiling in liver cancer: another new page.
Transl Gastroenterol Hepatol. 2019 Jun 21;4:47. doi: 10.21037/tgh.2019.06.03. eCollection 2019.
10
FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.
J Exp Clin Cancer Res. 2019 May 9;38(1):188. doi: 10.1186/s13046-019-1202-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验